Predictive factors for cure after immunosuppressive therapy of XXXX .

@entity1 @entity2214 @entity5 @entity2150 @entity2590 @entity1778 @entity7965
In a previous study, we evaluated efficacy of repeated antilymphocyte globulin (ALG) treatment for @entity1 with severe @entity2150 not responding to an initial ALG treatment or relapsing after initial response to ALG. We now searched in the same cohort of @entity1 for differences between @entity1 who responded to treatment and remained free of complications and those who relapsed or developed a @entity2214 . From 107 @entity1 surviving for more than 1 year after immunosuppression, 34 remained free from complications after the first course of ALG, and 73 presented an event defined as relapse of @entity2150 , development of a @entity2214 such as @entity7965 , @entity2590 or @entity1778 , or appearance of a solid @entity5 . We compared these two groups for survival, clinical performance and blood counts during follow-up. Survival probability was 93% for the event-free @entity1 , and 55% for the @entity1 with a complication event (p = 0.0003). Event-free @entity1 had a higher incidence of complete remission (71%), were more often free of immunosuppressive treatment (79%) and independent of transfusions (100%), and had a higher Karnofsky score (91% with a score > or =90%) as compared to the group with events (29, 37, 67, 48%; p < or = 0.0002). At 1 and 3 years, event-free @entity1 had significantly higher leukocyte and neutrophil counts, as compared to @entity1 with a complication (p < 0.05). However, at 3 and 5 years, event-free @entity1 had borderline higher platelet counts (p = 0.056, p = 0.078) and hemoglobin (p = 0. 097, p = 0.061). The coefficient of variation as an expression of the variability of the results in each group was systematically lower at 3, 5 and 10 years in the group of event-free @entity1 . Despite some differences between the two groups, our data support the hypothesis that @entity1 with long-lasting remissions should not be considered as definitively cured of @entity2150 .
